Literature DB >> 23490442

In vivo bioluminescence imaging validation of a human biopsy-derived orthotopic mouse model of glioblastoma multiforme.

Monika A Jarzabek1, Peter C Huszthy, Kai O Skaftnesmo, Emmet McCormack, Patrick Dicker, Jochen H M Prehn, Rolf Bjerkvig, Annette T Byrne.   

Abstract

Glioblastoma multiforme (GBM), the most aggressive brain malignancy, is characterized by extensive cellular proliferation, angiogenesis, and single-cell infiltration into the brain. We have previously shown that a xenograft model based on serial xenotransplantation of human biopsy spheroids in immunodeficient rodents maintains the genotype and phenotype of the original patient tumor. The present work further extends this model for optical assessment of tumor engraftment and growth using bioluminescence imaging (BLI). A method for successful lentiviral transduction of the firefly luciferase gene into multicellular spheroids was developed and implemented to generate optically active patient tumor cells. Luciferase-expressing spheroids were injected into the brains of immunodeficient mice. BLI photon counts and tumor volumes from magnetic resonance imaging (MRI) were correlated. Luciferase-expressing tumors recapitulated the histopathologic hallmarks of human GBMs and showed proliferation rates and microvessel density counts similar to those of wild-type xenografts. Moreover, we detected widespread invasion of luciferase-positive tumor cells in the mouse brains. Herein we describe a novel optically active model of GBM that closely mimics human pathology with respect to invasion, angiogenesis, and proliferation indices. The model may thus be routinely used for the assessment of novel anti-GBM therapeutic approaches implementing well-established and cost-effective optical imaging strategies.

Entities:  

Mesh:

Year:  2013        PMID: 23490442

Source DB:  PubMed          Journal:  Mol Imaging        ISSN: 1535-3508            Impact factor:   4.488


  14 in total

Review 1.  New cast for a new era: preclinical cancer drug development revisited.

Authors:  Grit S Herter-Sprie; Andrew L Kung; Kwok-Kin Wong
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

2.  Pre-clinical imaging for establishment and comparison of orthotopic non-small cell lung carcinoma: in search for models reflecting clinical scenarios.

Authors:  Rozina Aktar; Antje Dietrich; Falk Tillner; Shady Kotb; Steffen Löck; Henning Willers; Michael Baumann; Mechthild Krause; Rebecca Bütof
Journal:  Br J Radiol       Date:  2018-10-11       Impact factor: 3.039

3.  Sonoporation for Augmenting Chemotherapy of Pancreatic Ductal Adenocarcinoma.

Authors:  Jason Castle; Spiros Kotopoulis; Flemming Forsberg
Journal:  Methods Mol Biol       Date:  2020

4.  18F-FET microPET and microMRI for anti-VEGF and anti-PlGF response assessment in an orthotopic murine model of human glioblastoma.

Authors:  Mette Kjoelhede Nedergaard; Signe Regner Michaelsen; Thomas Urup; Helle Broholm; Henrik El Ali; Hans Skovgaard Poulsen; Marie-Thérése Stockhausen; Andreas Kjaer; Ulrik Lassen
Journal:  PLoS One       Date:  2015-02-13       Impact factor: 3.240

5.  Transgenic mouse model expressing P53(R172H), luciferase, EGFP, and KRAS(G12D) in a single open reading frame for live imaging of tumor.

Authors:  Hye-Lim Ju; Diego F Calvisi; Hyuk Moon; Sinhwa Baek; Silvia Ribback; Frank Dombrowski; Kyung Joo Cho; Sook In Chung; Kwang-Hyub Han; Simon Weonsang Ro
Journal:  Sci Rep       Date:  2015-01-27       Impact factor: 4.379

6.  Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models.

Authors:  M A Jarzabek; V Amberger-Murphy; J J Callanan; C Gao; A M Zagozdzon; L Shiels; J Wang; K L Ligon; B E Rich; P Dicker; W M Gallagher; J H M Prehn; A T Byrne
Journal:  Br J Cancer       Date:  2014-11-06       Impact factor: 7.640

7.  Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant.

Authors:  Z Zakaria; A Tivnan; L Flanagan; D W Murray; M Salvucci; B W Stringer; B W Day; A W Boyd; D Kögel; M Rehm; D F O'Brien; A T Byrne; J H M Prehn
Journal:  Br J Cancer       Date:  2015-12-10       Impact factor: 7.640

8.  Establishment of a bioluminescence model for microenvironmentally induced oral carcinogenesis with implications for screening bioengineered scaffolds.

Authors:  Salwa Suliman; Himalaya Parajuli; Yang Sun; Anne Christine Johannessen; Anna Finne-Wistrand; Emmet McCormack; Kamal Mustafa; Daniela Elena Costea
Journal:  Head Neck       Date:  2015-08-14       Impact factor: 3.147

9.  First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma.

Authors:  Oystein Helland; Mihaela Popa; Olav K Vintermyr; Anders Molven; Bjørn Tore Gjertsen; Line Bjørge; Emmet McCormack
Journal:  PLoS One       Date:  2014-03-04       Impact factor: 3.240

10.  Influence of handling conditions on the establishment and propagation of head and neck cancer patient derived xenografts.

Authors:  Andrew P Stein; Sandeep Saha; Cheng Z Liu; Gregory K Hartig; Paul F Lambert; Randall J Kimple
Journal:  PLoS One       Date:  2014-06-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.